BRINGING QUALITY, EXPERTISE
AND TRUST TO CANNABIS

We put patients and people first. By providing a portfolio of high-quality cannabis-based health and wellness solutions, leveraging data and research to fuel innovation, and improving access to cannabis and plant-based solutions, we aim to lead the industry.

Columbia Care Inc. is one of the largest and most experienced multi-state operators in the medical cannabis industry, with licenses in 15 jurisdictions in the US and the EU.

With over 1,000,000 successful sales transactions since its inception, Columbia Care is a patient-centered organization setting the standard for compassion, professionalism, quality, caring and innovation, working in collaboration with some of the most renowned and innovative teaching hospitals and medical centers in the world. The Company is committed to providing the type of education and transparency patients deserve and quality of product that clinicians expect.

With six-plus years of strong organic growth, disciplined operationalization of licenses, over 1 million sales transactions since inception, and having built 14 state-by-state vertically integrated operations, including 54 facilities in operation or development, and 35 licenses in 15 markets, we understand regulators, compliance, cultivation, manufacturing, quality control, physicians, caregivers, dispensaries, patients, and data inherent for success in this industry.

In addition to our medical cannabis products, we also offer a variety of health and wellness brands and products, including our own hemp CBD brands that are full spectrum, independent 3rd party tested, organic, GMO-free, and produced in cGMP-compliant facilities. Our flagship hemp CBD brand, Columbia Care Platinum Label, aims to set the standard in potency and purity.

COLUMBIA CARE LAUNCHES "100,000,000 WAYS TO BREAK THE OPIOID CRISIS" INITIATIVE

Columbia Care to partner with experts at Montefiore Medical Center and Albert Einstein College of Medicine for initial phase of nationwide study on medical cannabis’s impact on opioid use for pain

NEW YORK–(BUSINESS WIRE)– Columbia Care Inc. (“Columbia Care”, or the “Company”) (NEO: CCHW), a leading international medical cannabis company, today announced the launch of its new initiative, “100,000,000 Ways to Break the Opioid Crisis,” a nationwide effort to test whether precisely-formulated medical cannabis can be a safe and effective alternative to opioids for pain.

Columbia Care is kicking off the “100,000,000 Ways to Break the Opioid Crisis” initiative by providing its precisely-formulated pharmaceutical-quality cannabis-based medicines for a precedent-setting study to determine whether medical cannabis can reduce participants’ dependence on opioid use in managing pain. This study, which is being conducted at Montefiore Medical Center and Albert Einstein College of Medicine in the Bronx, will add to the body of knowledge to inform healthcare practices and public policies in this arena. The study is expected to be expanded to other hospitals throughout New York State and, ultimately, to other states where Columbia Care’s formulated medical cannabis products are also available.

Renowned addiction experts Dr. Chinazo Cunningham and Dr. Julia Arnsten, who are both researchers at Montefiore and Einstein, are leading the study.

DISCOVER HOW COLUMBIA CARE ARE DEVELOPING PRODUCTS TO MEET AN UNMET CLINICAL NEED IN WOMEN SUFFERING FROM PELVIC CONDITIONS.

As one of the nation’s most experienced producers of medical cannabis products, Columbia Care is committed to helping patients suffering from a wide range of state permitted qualifying conditions, including pelvic conditions.

It is a fact that female pelvic organs have a very high density of cannabinoid receptors (Brents, 2016). Current knowledge of the endocannabinoid system doesn’t explain the reason for this high number of receptors in the gynaecological urinary tract, but often this system is used to maintain a homeostatic balance in the body. The fact that the vagina has a mucous membrane that can readily absorb medicinal products makes vaginal suppositories uniquely suited to treating conditions affecting the women’s reproductive system, as they target the issue right at its source. It is also obvious that only quality products should be delivered in this manner to avoid irritation and additional inflammation.

The increased public awareness surrounding the use of cannabis for women’s health and the promising research discussed throughout this article put Columbia Care at the forefront of this movement with the debut of their pharmaceutical quality vaginal suppositories. This article summarises the existing scientific evidence regarding cannabis for women’s health concerns, and how these products are already transforming the treatment paradigm for women suffering from these conditions.

Columbia Care is constantly searching for new ways to address conditions associated with women’s health and as a result of these efforts, it has become one of the only medical cannabis companies to develop vaginal suppositories. These are the newest medicinal format addition to their proprietary portfolio of cannabis-based medicines, which already includes tinctures, vaporisation oils and hard-pressed tablets. All formulations are available for women’s health indications (within state guidelines), and for many of these conditions, such as insomnia, one of these traditional formats may be the best option. The vaginal suppositories are an important option for patients who may want rapid delivery of cannabinoids to the pelvic organs.

COLUMBIA CARE AND MOELLER PHARMA GMBH ENTER INTO EXCLUSIVE AGREEMENT TO DEVELOP PORTFOLIO OF PROPRIETARY, PLANT-BASED COMBINATION CANNABINOID FUNCTIONAL HEALTH AND WELLNESS PRODUCTS August 30, 2019

Columbia Care partners with FDA approved, GMP certified German developer and manufacturer of ultra-high quality herbal extracts, organic plant-based combination supplements and functional beverages with 75-year history of serving the pharmaceutical and food industries through its well established EU retail network of health food stores, drug stores, hypermarkets and independent pharmacies

R&D collaboration will provide the basis to develop a unique portfolio of products combining Columbia Care’s proprietary, pharmaceutical-quality cannabis-based formulations and Moeller’s deep repository of plant-derived botanical and homeopathic supplements and medicines

NEW YORK–(BUSINESS WIRE)–
Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, announced that it has entered into an exclusive agreement with Moeller Pharma GmbH (“Moeller”), a GMP-certified German producer of high-quality herbal extracts, functional beverages and plant-derived combination supplements for the pharmaceutical and food industries, to develop a portfolio of proprietary cannabinoid-infused products to be sold globally, beginning with Europe and the US.

Moeller has been a trusted name in German households for more than 75 years, well known for the production and distribution of over 100 different high-quality fruit juices, plant-based functional drinks, supplements and other products sold through its established network of health food stores, drug stores and hypermarkets in Europe. Through its relationships with six of the largest German wholesalers, Moeller has access to over 22,000 independent pharmacies and retailers in Germany alone and currently produces more than 72 unique extracts and distillates of medicinal plants at scale for leading pharmaceutical companies. Moeller also possesses significant production capacity, currently extracting more than 600 metric tons of biomass per year at its state-of-the-art, FDA approved, Good Manufacturing Practice (GMP) certified facility in Germany.

Under the terms of the agreement, Columbia Care will contribute its GMP/GAP industrial hemp biomass, chemistry and extraction expertise as well as its cannabinoid extraction capabilities for use in health and wellness products while Moeller will provide its library of plant-based extracts, combination products, manufacturing capabilities, distribution channels and experience in creating popular functional consumer products for the global pharmaceutical, wellness and food markets. The parties will exclusively collaborate on research and development (R&D) efforts to develop a unique, patentable portfolio of cannabinoid-infused health and wellness products. Finished products will be manufactured under GMP conditions at Moeller’s German manufacturing facility.

10.10.25 Specials

Never miss a top pick!